(PRME) Prime Medicine, Common Stock - Ratings and Ratios
Gene Editing Technology, Prime Editing, pegRNA, Cas Domains, RT Domain
Description: PRME Prime Medicine, Common Stock
Prime Medicine, Inc. is a biotechnology company that focuses on developing genetic therapies using its proprietary Prime Editing technology, a gene editing tool that enables precise modifications to the genome without causing double-stranded breaks. The companys technology has the potential to address a wide range of diseases, and it is currently collaborating with Cimeio Therapeutics to develop treatments for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome.
From a financial perspective, Prime Medicines Market Cap stands at $317.73M USD, indicating a relatively small-cap company with significant growth potential. The absence of a P/E ratio suggests that the company is not yet profitable, which is common in the biotechnology industry where companies often invest heavily in R&D before generating revenue. The Return on Equity (RoE) of -125.05% indicates significant losses, likely due to the high R&D expenses associated with developing new therapies.
To further evaluate Prime Medicines potential, we can consider additional KPIs such as the companys cash runway, R&D expenses as a percentage of revenue, and the number of ongoing clinical trials. A longer cash runway and a higher R&D investment as a percentage of revenue could indicate a stronger potential for future growth. Additionally, the progress of the companys pipeline, including the number of candidates in clinical trials and the expected timelines for regulatory approvals, will be crucial in determining the companys future success.
From a growth perspective, the collaboration with Cimeio Therapeutics and the development of Prime Edited Shielded-Cell & Immunotherapy Pairs for various diseases could be a significant catalyst for the companys growth. The success of these collaborations and the advancement of the companys pipeline will be critical in driving the companys stock price. As a Trading Analyst, it is essential to closely monitor the companys progress, including any updates on clinical trials, regulatory approvals, and partnerships, to make informed investment decisions.
PRME Stock Overview
| Market Cap in USD | 595m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2022-10-20 |
PRME Stock Ratings
| Growth Rating | -44.4% |
| Fundamental | 39.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -1.92% |
| Analyst Rating | 4.17 of 5 |
PRME Dividends
Currently no dividends paidPRME Growth Ratios
| Growth Correlation 3m | 19.4% |
| Growth Correlation 12m | -12.9% |
| Growth Correlation 5y | -94.1% |
| CAGR 5y | -33.89% |
| CAGR/Max DD 3y | -0.36 |
| CAGR/Mean DD 3y | -0.49 |
| Sharpe Ratio 12m | -1.20 |
| Alpha | 0.03 |
| Beta | 0.961 |
| Volatility | 102.07% |
| Current Volume | 4044.9k |
| Average Volume 20d | 2813.7k |
| Stop Loss | 4.3 (-7.5%) |
| Signal | -0.74 |
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-199.3m TTM) > 0 and > 6% of Revenue (6% = 297.7k TTM) |
| FCFTA -0.47 (>2.0%) and ΔFCFTA 20.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1757 % (prev 234.3%; Δ 1523 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.36 (>3.0%) and CFO -99.9m > Net Income -199.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.56 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (129.2m) change vs 12m ago 8.39% (target <= -2.0% for YES) |
| Gross Margin -37.86% (prev 86.77%; Δ -124.6pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.84% (prev 24.67%; Δ -22.82pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -16.15
| (A) 0.31 = (Total Current Assets 121.3m - Total Current Liabilities 34.1m) / Total Assets 279.0m |
| (B) -2.84 = Retained Earnings (Balance) -791.7m / Total Assets 279.0m |
| warn (B) unusual magnitude: -2.84 — check mapping/units |
| (C) -0.77 = EBIT TTM -206.1m / Avg Total Assets 269.4m |
| (D) -3.63 = Book Value of Equity -791.7m / Total Liabilities 218.1m |
| Total Rating: -16.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.97
| 1. Piotroski 0.50pt = -4.50 |
| 2. FCF Yield -18.71% = -5.0 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 3.26 = -1.15 |
| 5. Debt/Ebitda -1.00 = -2.50 |
| 7. RoE -156.2% = -2.50 |
| 8. Rev. Trend 17.43% = 1.31 |
| 9. EPS Trend 66.40% = 3.32 |
What is the price of PRME shares?
Over the past week, the price has changed by +19.54%, over one month by +32.86%, over three months by +187.93% and over the past year by +16.25%.
Is Prime Medicine, Common Stock a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PRME is around 3.59 USD . This means that PRME is currently overvalued and has a potential downside of -22.8%.
Is PRME a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 4
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PRME price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.9 | 48.2% |
| Analysts Target Price | 6.9 | 48.2% |
| ValueRay Target Price | 4 | -14.8% |
Last update: 2025-09-05 04:56
PRME Fundamental Data Overview
CCE Cash And Equivalents = 98.3m USD (Cash And Short Term Investments, last quarter)
P/S = 120.0232
P/B = 9.7837
Beta = 2.408
Revenue TTM = 4.96m USD
EBIT TTM = -206.1m USD
EBITDA TTM = -199.2m USD
Long Term Debt = 184.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 14.5m USD (from shortTermDebt, last quarter)
Debt = 198.6m USD (Calculated: Short Term 14.5m + Long Term 184.0m)
Net Debt = 65.9m USD (from netDebt column, last quarter)
Enterprise Value = 695.6m USD (595.4m + Debt 198.6m - CCE 98.3m)
Interest Coverage Ratio = unknown (Ebit TTM -206.1m / Interest Expense TTM 0.0)
FCF Yield = -18.71% (FCF TTM -130.2m / Enterprise Value 695.6m)
FCF Margin = -2624 % (FCF TTM -130.2m / Revenue TTM 4.96m)
Net Margin = -4017 % (Net Income TTM -199.3m / Revenue TTM 4.96m)
Gross Margin = -37.86% ((Revenue TTM 4.96m - Cost of Revenue TTM 6.84m) / Revenue TTM)
Tobins Q-Ratio = -0.88 (set to none) (Enterprise Value 695.6m / Book Value Of Equity -791.7m)
Interest Expense / Debt = 0.22% (Interest Expense 434.0k / Debt 198.6m)
Taxrate = 21.0% (US default)
NOPAT = -206.1m (EBIT -206.1m, no tax applied on loss)
Current Ratio = 3.56 (Total Current Assets 121.3m / Total Current Liabilities 34.1m)
Debt / Equity = 3.26 (Debt 198.6m / last Quarter total Stockholder Equity 60.9m)
Debt / EBITDA = -1.00 (Net Debt 65.9m / EBITDA -199.2m)
Debt / FCF = -1.53 (Debt 198.6m / FCF TTM -130.2m)
Total Stockholder Equity = 127.6m (last 4 quarters mean)
RoA = -71.42% (Net Income -199.3m, Total Assets 279.0m )
RoE = -156.2% (Net Income TTM -199.3m / Total Stockholder Equity 127.6m)
RoCE = -66.13% (Ebit -206.1m / (Equity 127.6m + L.T.Debt 184.0m))
RoIC = -161.5% (set to none) (NOPAT -206.1m / Invested Capital 127.6m)
WACC = 7.21% (E(595.4m)/V(794.0m) * Re(9.56%)) + (D(198.6m)/V(794.0m) * Rd(0.22%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 78.79 | Cagr: 2.90%
Discount Rate = 9.56% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -130.2m)
EPS Correlation: 66.40 | EPS CAGR: 114.1% | SUE: 0.17 | # QB: 0
Revenue Correlation: 17.43 | Revenue CAGR: 161.6% | SUE: -0.14 | # QB: 0
Additional Sources for PRME Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle